CytRx Corporation (CYTR) Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
5/5/2014 9:00:37 AM
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, presented updated progression-free survival (PFS) and overall survival (OS) results from its completed Phase 1b/2 clinical trial of aldoxorubicin in patients with advanced soft tissue sarcoma (STS). The data were presented as part of CytRx’s Research and Development Day which took place Friday, May 2, 2014 at the Harvard Club in New York City.
Help employers find you! Check out all the jobs and post your resume.
comments powered by